遠大醫藥(00512.HK)擬1200萬美元收購香港東海醫療餘下股權
格隆匯 2 月 8日丨遠大醫藥(00512.HK)宣佈，於2021年2月8日，公司作為買方擬向上海產融(由公司的其中一名控股股東胡凱軍全資擁有的北京遠大持有70%的公司)收購香港東海醫療有限公司餘下的股本權益，代價為1200萬美元。
據悉，目標公司為由公司及賣方於2017年11月成立之合營企業。目標公司主要從事銷售心腦血管醫療設備之業務，及其主要資產為持有Conavi的1,043,115股優先股，及"Novasight Hybrid"系列及"ForesightI CE"系列等產品在中國大陸、香港、澳門及台灣等地區之二十年獨家代理權。根據公司與賣方訂立的協議，目標公司的總投資金額為約1500萬美元，其中公司會投入不超過約750萬美元並取得目標公司不多於49.9%的股本權益。於公吿日期，賣方及公司分別為目標公司的約50.13%及49.87%已發行股份的登記持有人，但因為賣方已投入約美金750萬元及公司只投入了約美金330萬元，因此根據公司與賣方訂立的協議，公司僅能根據其實際投資金額的比例，行使目標公司的約22.3%股本控制權。
公吿稱，Conavi的全球創新醫療器械產品"NOVASIGHT"已在美國、加拿大和日本上市，並已獲得中國國家藥品監督管理局之創新醫療器械特別審批資格。NOVASIGHT為一款血管內超聲光學同步成像產品，是目前全球唯一一款商業化的雙模成像系統，其融合了血管超聲和光學相干斷層掃描兩種成像技術，可以同時、同向、同軸、同位的展示超聲及光學圖像，由於其兼具高解析度與高穿透力的雙重功能，因此可以實現?遠近兼顧?的腔內影像並滿足導管室多種臨牀應用場景，該產品也是全球首款獲得美國Food and Drug Administration (FDA)批准的血管內超聲光學成像融合系統，在冠脈血管成像和腔內介入手術領域都有廣闊的應用前景。
Conavi研發的另一款三維心腔內超聲成像系統"FORESIGHT"，能夠從心腔內更精確呈現完整的影像資訊，對於射頻消融或者結構性心臟病術前診斷及術中引導都能發揮重要作用。
公司之管理層認為Conavi的產品已展示美好的前景，而收購目標公司餘下的股本以增加與Conavi的起步階段所佔的份額亦為符合公司的利益，而該等投資亦與集團打造國際領先的泛血管精準介入診療平台的佈局與規劃完美契合，有助於集團在精準介入領域實現診療一體化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
